1. Guidance for industry. Clinical pharmacology. Exposure-response relationships: study design, data analysis, and regulatory applications. United States Food and Drug Administration. Center for Drug Evaluation and Research.
http://www.fda.gov/cder/guidance/index.htm
2. (1994) International Conference on Harmonisation. Guidance on dose response information to support drug registration. Fed Regist 59(216):55972–55976
3. Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J (1985) Prospective validation of a pharmacologically based dosing scheme for the cisdiammine-dichloroplatinum(II) analogue diammine-cyclobutanedicarboxylatoplatinum. Cancer Res 45:6502–6506
4. O’Dwyer PJ, LaCreta F, Engstrom PF et al (1991) Phase I/pharmacokinetic reevaluation of thioTEPA. Cancer Res 51(12):3171–3176
5. Fanucci MP, Walsh TD, Fleisher M et al (1987) Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res 47(12):3303–3308